Şunu aradınız:: galactosidase (İngilizce - Estonca)

alpha-galactosidase
α-galaktosidaas

alpha-galactosidase:
a-galaktosidaas:

50 u alpha-galactosidase
50 u α-galaktosidaasi

100 u alpha-galactosidase/kg
100 u α-galaktosidaasi/kg

1000 u [1] alpha-galactosidase/g,
1000 u [1]α-galaktosidaasi grammi kohta

1000 u [1] alpha-galactosidase/g
1000 u [1] α-galaktosidaasi/g

100 u alpha-galactosidase/kg of complete feed,
100 u α-galaktosidaasi täissööda kg kohta;

agalsidase alfa is a form of the human enzyme α -galactosidase.
agalsidaas alfa on inimensüümi α - galaktosidaasi vorm.

it is produced by switching on the gene for α-galactosidase a in cells.
seda toodetakse α-galaktosidaasi a geeni aktiviseerimise teel rakkudes.

galafold is only for use in patients with certain mutations in the alpha-galactosidase a gene.
galafold on ette nähtud kasutamiseks ainult alfa-galaktosidaas a geeni teatud mutatsioonidega patsientidel.

patients with fabry disease do not have enough of an enzyme called alpha-galactosidase a.
fabry tõvega patsientidel esineb alfa- galatosidaas a- ks nimetatava ensüümi vaegus.

fabrazyme is designed to replace the human enzyme alpha galactosidase a, which is lacking in patients with fabry disease.
fabrazyme on ette nähtud asendama inimensüümi alfa-galaktosidaas a-d, mis fabry tõvega patsientidel puudub.

fabrazyme is designed to replace the human enzyme alpha-galactosidase a, which people with fabry disease are lacking.
fabrazyme on mõeldud asendamaks kehaomast ensüümi alfa - galaktosidaas a, millest fabry tõbe põdevate inimeste organismis on nappus.

replagal is designed to replace the human enzyme alpha-galactosidase a, which is lacking in people with fabry disease.
replagal on ette nähtud asendama inimensüümi alfa-galaktosidaas a, mis fabry tõvega patsientidel napib.

as α-galactosidase a is itself an enzyme, it would be an unlikely candidate for cytochrome p450 mediated drug-drug interactions.
kuna α-galaktosidaas a on ise ensüüm, on tema puhul ravimite koostoime tsütokroom p450 vahendusel ebatõenäoline.

fabrazyme is used as enzyme replacement therapy in fabry disease, where the level of α - galactosidase enzyme activity is absent or lower than normal.
fabrazyme' i kasutatakse fabry haiguse, mille puhul α- galaktosidaasi ensümaatiline aktiivsus puudub või on langenud, ensüümasendusraviks.

fabry disease is caused by the lack of or a faulty enzyme called alpha-galactosidase a (α–gal a).
fabry tõbe põhjustab ensüümi alfagalaktosidaas a (α–gal a) puudumine või puudulikkus.

fabrazyme contains the active substance agalsidase beta and is used as enzyme replacement therapy in fabry disease, where the level of -galactosidase enzyme activity is absent or lower than normal.
fabrazyme'i sisaldab toimeainena beetaagalsidaasi ja seda kasutatakse fabry haiguse ensüümasendusraviks, mille puhul -galaktosidaasi ensümaatiline aktiivsus puudub või on langenud.

fabrazyme should not be administered with chloroquine, amiodarone, benoquin or gentamycin due to a theoretical risk of inhibition of intra-cellular α -galactosidase activity.
fabrazyme´i ei tohiks manustada koos klorokviini, amiodarooni, benokviini või gentamütsiiniga rakusisese α- galaktosidaasi aktiivsuse pärssimise teoreetilise võimaluse tõttu.

replagal is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (α-galactosidase a deficiency).
replagal on näidustatud pikaajaliseks ensüümasendusraviks patsientidel, kelle fabry tõve diagnoos (α-galaktosidaas a vaegus) on kinnitust leidnud.